QQQ   316.25 (+1.09%)
AAPL   123.08 (+1.73%)
MSFT   233.28 (+1.87%)
FB   262.85 (+3.20%)
GOOGL   2,034.39 (+0.91%)
AMZN   3,080.06 (+0.75%)
TSLA   674.65 (-1.11%)
NVDA   549.30 (+3.19%)
BABA   241.08 (+0.37%)
CGC   32.69 (-1.57%)
GE   12.69 (-0.55%)
MU   91.90 (+4.29%)
NIO   46.26 (-1.17%)
AMD   84.49 (+2.51%)
T   28.05 (-2.03%)
F   11.83 (+0.60%)
ACB   10.71 (-1.02%)
DIS   189.85 (-0.59%)
BA   212.83 (-1.67%)
NFLX   544.60 (-0.38%)
BAC   35.04 (-2.48%)
QQQ   316.25 (+1.09%)
AAPL   123.08 (+1.73%)
MSFT   233.28 (+1.87%)
FB   262.85 (+3.20%)
GOOGL   2,034.39 (+0.91%)
AMZN   3,080.06 (+0.75%)
TSLA   674.65 (-1.11%)
NVDA   549.30 (+3.19%)
BABA   241.08 (+0.37%)
CGC   32.69 (-1.57%)
GE   12.69 (-0.55%)
MU   91.90 (+4.29%)
NIO   46.26 (-1.17%)
AMD   84.49 (+2.51%)
T   28.05 (-2.03%)
F   11.83 (+0.60%)
ACB   10.71 (-1.02%)
DIS   189.85 (-0.59%)
BA   212.83 (-1.67%)
NFLX   544.60 (-0.38%)
BAC   35.04 (-2.48%)
QQQ   316.25 (+1.09%)
AAPL   123.08 (+1.73%)
MSFT   233.28 (+1.87%)
FB   262.85 (+3.20%)
GOOGL   2,034.39 (+0.91%)
AMZN   3,080.06 (+0.75%)
TSLA   674.65 (-1.11%)
NVDA   549.30 (+3.19%)
BABA   241.08 (+0.37%)
CGC   32.69 (-1.57%)
GE   12.69 (-0.55%)
MU   91.90 (+4.29%)
NIO   46.26 (-1.17%)
AMD   84.49 (+2.51%)
T   28.05 (-2.03%)
F   11.83 (+0.60%)
ACB   10.71 (-1.02%)
DIS   189.85 (-0.59%)
BA   212.83 (-1.67%)
NFLX   544.60 (-0.38%)
BAC   35.04 (-2.48%)
QQQ   316.25 (+1.09%)
AAPL   123.08 (+1.73%)
MSFT   233.28 (+1.87%)
FB   262.85 (+3.20%)
GOOGL   2,034.39 (+0.91%)
AMZN   3,080.06 (+0.75%)
TSLA   674.65 (-1.11%)
NVDA   549.30 (+3.19%)
BABA   241.08 (+0.37%)
CGC   32.69 (-1.57%)
GE   12.69 (-0.55%)
MU   91.90 (+4.29%)
NIO   46.26 (-1.17%)
AMD   84.49 (+2.51%)
T   28.05 (-2.03%)
F   11.83 (+0.60%)
ACB   10.71 (-1.02%)
DIS   189.85 (-0.59%)
BA   212.83 (-1.67%)
NFLX   544.60 (-0.38%)
BAC   35.04 (-2.48%)
Log in
NASDAQ:XGN

Exagen Stock Forecast, Price & News

$19.50
+0.26 (+1.35 %)
(As of 02/26/2021 10:41 AM ET)
Add
Compare
Today's Range
$19.50
Now: $19.50
$19.75
50-Day Range
$14.47
MA: $16.85
$19.50
52-Week Range
$10.29
Now: $19.50
$22.99
Volume130 shs
Average Volume29,444 shs
Market Capitalization$246.71 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Exagen Inc. develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enable rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company's products also comprise AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of eight autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a ten-biomarker panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease requiring aggressive therapy, such as anti-TNF biologics; and AVISE PC4d that measures platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a six-biomarker blood test; AVISE MTX, a patented and validated blood test that measures levels of MTXPG; and AVISE HCQ, a blood test designed to help rheumatologists objectively monitor levels of hydroxychloroquine. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Headlines

A Look At Exagen's (NASDAQ:XGN) Share Price Returns
February 15, 2021 |  finance.yahoo.com
Exagen Inc. To Participate in 2021 ICR Conference
January 5, 2021 |  benzinga.com
3 Beaten-Down MedTech Stocks Set to Stage a Comeback in 2021
December 11, 2020 |  finance.yahoo.com
Exagen Inc. to Participate in December Investor Conferences
November 18, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XGN
CUSIPN/A
CIKN/A
Phone760 560 1501
Employees153
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$40.39 million
Book Value$4.43 per share

Profitability

Net Income$-12,040,000.00

Miscellaneous

Market Cap$246.71 million
Next Earnings Date3/24/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.55 out of 5 stars

Medical Sector

392nd out of 1,956 stocks

Medical Laboratories Industry

6th out of 39 stocks

Analyst Opinion: 2.5Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$19.50
+0.26 (+1.35 %)
(As of 02/26/2021 10:41 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XGN News and Ratings via Email

Sign-up to receive the latest news and ratings for XGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Exagen (NASDAQ:XGN) Frequently Asked Questions

Is Exagen a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Exagen stock.
View analyst ratings for Exagen
or view top-rated stocks.

What stocks does MarketBeat like better than Exagen?

Wall Street analysts have given Exagen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Exagen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Exagen's next earnings date?

Exagen is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for Exagen
.

How were Exagen's earnings last quarter?

Exagen Inc. (NASDAQ:XGN) released its quarterly earnings results on Tuesday, November, 10th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.13. The business had revenue of $10.78 million for the quarter, compared to the consensus estimate of $9.03 million. Exagen had a negative net margin of 39.49% and a negative trailing twelve-month return on equity of 29.10%.
View Exagen's earnings history
.

How has Exagen's stock been impacted by Coronavirus?

Exagen's stock was trading at $19.56 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, XGN stock has decreased by 0.3% and is now trading at $19.50.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for XGN?

4 Wall Street analysts have issued twelve-month price targets for Exagen's shares. Their forecasts range from $18.00 to $32.00. On average, they expect Exagen's stock price to reach $23.33 in the next twelve months. This suggests a possible upside of 19.7% from the stock's current price.
View analysts' price targets for Exagen
or view top-rated stocks among Wall Street analysts.

Who are Exagen's key executives?

Exagen's management team includes the following people:
  • Mr. Fortunato Rocca, CEO, Pres & Director (Age 60, Pay $545.69k)
  • Mr. Kamal Adawi, CFO & Corp. Sec. (Age 42, Pay $356.04k)
  • Dr. Anja Kammesheidt Ph.D., Chief Scientific Officer
  • Mr. John Wegener, Sr. VP of Sales and Marketing (Age 52)
  • Mr. Mark Hazeltine, Sr. VP of Fin. & Corp. Devel.
  • Dr. Debra Jeske Zack, Chief Medical Officer (Age 64)

What is Ron Rocca's approval rating as Exagen's CEO?

5 employees have rated Exagen CEO Ron Rocca on Glassdoor.com. Ron Rocca has an approval rating of 80% among Exagen's employees.

Who are some of Exagen's key competitors?

When did Exagen IPO?

(XGN) raised $50 million in an IPO on Thursday, September 19th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. Cowen, Cantor and William Blair acted as the underwriters for the IPO.

What is Exagen's stock symbol?

Exagen trades on the NASDAQ under the ticker symbol "XGN."

Who are Exagen's major shareholders?

Exagen's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.07%), Perkins Capital Management Inc. (1.05%), Victory Capital Management Inc. (0.58%), Brown Advisory Inc. (0.14%), Bank of New York Mellon Corp (0.11%) and JPMorgan Chase & Co. (0.11%). Company insiders that own Exagen stock include Bio-Exagen LP HIG, Hunt Holdings Limited Partners, James L L Tullis and Nmsic Co-Investment Fund, LP.
View institutional ownership trends for Exagen
.

Which major investors are selling Exagen stock?

XGN stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, Wells Fargo & Company MN, Brown Advisory Inc., Victory Capital Management Inc., and Bank of New York Mellon Corp. Company insiders that have sold Exagen company stock in the last year include Hunt Holdings Limited Partners, James L L Tullis, and Nmsic Co-Investment Fund, LP.
View insider buying and selling activity for Exagen
or view top insider-selling stocks.

Which major investors are buying Exagen stock?

XGN stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Perkins Capital Management Inc., and JPMorgan Chase & Co..
View insider buying and selling activity for Exagen
or or view top insider-buying stocks.

How do I buy shares of Exagen?

Shares of XGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exagen's stock price today?

One share of XGN stock can currently be purchased for approximately $19.50.

How much money does Exagen make?

Exagen has a market capitalization of $246.71 million and generates $40.39 million in revenue each year. The company earns $-12,040,000.00 in net income (profit) each year or ($8.46) on an earnings per share basis.

How many employees does Exagen have?

Exagen employs 153 workers across the globe.

What is Exagen's official website?

The official website for Exagen is www.exagen.com.

Where are Exagen's headquarters?

Exagen is headquartered at 1261 Liberty Way Suite C, VISTA CA, 92081.

How can I contact Exagen?

Exagen's mailing address is 1261 Liberty Way Suite C, VISTA CA, 92081. The company can be reached via phone at 760 560 1501 or via email at [email protected]


This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.